Efficacy of 1% atropine eye drops in retarding progressive axial myopia in Indian eyes

Abstract

Purpose:The aim of this study is to assess the efficacy of 1% atropine eye drops for the retardation of progressive axial myopia in Indian eyes.Methods:This prospective interventional cohort study included children aged 5–16 years. Both the eyes of myopic children with progressive increase of ≥−0.5D sphere/year with the best-corrected vision of ≥6/6 were treated with once a day application of 1% atropine eye drops and progressive addition photogray lenses. The progression of myopia after 1-year follow-up was analyzed.Results:Sixty eyes of thirty myopes were included in the study. The mean age was 10 years and 15 were girls. The mean baseline sphere was −5.2D (−2.5D–−13D). Mean duration of follow-up was 23 months (12–36 months). The baseline rate of progression was reduced from −0.6D/year (range −0.5D/year to −3D/year) to −0.2D/year (range 0D/year to −1.5D/year) after atropine therapy. Seventeen patients (57%) had to use the atropine in the daytime to reach the target progression of <−0.5D/year. There was no difference between the efficacy of atropine drops in the boys and girls (P = 0.6). The efficacy of atropine drops did not have a correlation with the age of the patients or the magnitude of baseline myopia (Pearson's r = 0).Conclusion:1% atropine eye drops was well tolerated and efficacious for the retardation of progressive myopia in Indian eyes. Effectiveness was better with daytime application. Further studies are necessary to assess the role of 1% atropine in the rapid progressors and patients poorly responding to low-dose atropine.

Atropine 0.01% as a Potential Myopia Prevention in Children with Dosage Effectivity Comparison: a Literature Review

“…Atropin merupakan alkaloid turunan tanaman herbal Atropa belladonna yang bertindak sebagai antagonis reseptor asetilkolin muskarinik yang memiliki afinitas kuat nonselektif kompetitif pada kelima jenis reseptor asetilkolin muskarinik (M1-M5) sehingga menyebabkan kelemahan pada otot siliaris dan iris lalu menyebabkan terjadi penurunan akomodasi dan terjadinya pelebaran pupil (Barathi et al, 2014;Carr and Stell, 2016;Huang et al, 2016;Kothari and Rathod, 2017;McBrien et al, 2013;Shih et al, 2016). Pada awalnya efek penurunan akomodasi ini dipercaya sebagai mekanisme yang berperan dalam pencegahan perkembangan miopia (Berntsen et al, 2013(Berntsen et al, , 2010Carr and Stell, 2016;CHOU et al, 1997).…”

“…Penggunaan atropin 1% sebagai obat tetes mata untuk pencegahan miopia yang lebih buruk sebenarnya sudah diteliti sejak sekitar tahun 1960 pada monyet (Kothari et al, 2017;Berntsen et al, 2010). Kemudian sejak sekitar tahun 1980 hingga 1990, penelitian mengenai penggunaan atropin baik 1% hingga 0.5% mulai sering dilakukan pada manusia (Brenner, 1985;CHOU et al, 1997;Pineles et al, 2017;SHIH et al, 1999) Namun, setelah digunakan sayangnya atropin dosis tinggi ini ternyata menimbulkan efek samping seperti mata lebih sensitif cahaya sehingga mudah merasa silau, adanya fobia cahaya, pandangan yang kabur terutama untuk jarak dekat, sikloplegik, dan efek sistemik seperti alergi, mulut kering, kulit memerah, dan konstipasi sehingga menghambat penggunaan obat ini (Huang et al, 2016;Clark et al, 2015;Pineles et al, 2017;Shih et al, 2016;Li et al, 2014;McBrien et al, 2013;Kothari et al, 2017;Carr et al, 2017). Oleh karena efek samping ini, anak-anak perlu menggunakan lensa fotokromik untuk menyaring sinar UV yang mengekspos retina (Chia et al, 2016;Chua, 2014;Shih et al, 2016).…”

Reduction of Myopia Burden and Progression

“…At the end of the 2-year study period, there was a Reduction of Myopia Burden and Progression DOI: http://dx.doi.org /10.5772/intechopen.85715 77% reduction in myopia progression with an unaltered axial length, compared to the control [37,38]. The study was originally conducted in Asia but was adopted by other countries due to its encouraging results [39][40][41][42][43]. Following a successful 2-year treatment phase, the patients displayed rebound phenomenon in the 1-year washout phase.…”

Allergic reactions to atropine eye drops for retardation of progressive myopia in children

“…Atropine eye drops are frequently used for retardation of progressive myopia in children. [ 1 2 ] Incidence of allergic conjunctivitis and allergic dermatitis (with 0.1% and 0.5% atropine eye drops) is reported to be 4.1% and 1.3%, respectively. [ 1 ] Contact dermatitis, allergic conjunctivitis, and interface dermatitis (ID) type reactions with 1% atropine eye drops are reported in adults.…”